Prescription drug · BLA
Cyramza (ramucirumab) NDC 0002-7669
Ramucirumab 10 mg/mL · Solution · Intravenous · Eli Lilly and Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0002-7669-01 | 00002766901 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7669-01) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 21, 2014 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cyramza
- Generic name (nonproprietary)
- ramucirumab
- Active ingredients
- Ramucirumab — 10 mg/mL
- Dosage form
- Solution
- Route
- Intravenous
- Labeler
- Eli Lilly and Company
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125477
- Marketing start
- Listing expires
- Other FDA classes
- VEGFR2 Inhibitors (Mechanism)
- Identifiers
- Product ID 0002-7669_161cb5e7-7955-45e5-bdde-9be94fdbe76aSPL ID 161cb5e7-7955-45e5-bdde-9be94fdbe76aSPL set ID c6080942-dee6-423e-b688-1272c2ae90d4RxCUI 1657775, 1657777, 1657780, 1657781UNII D99YVK4L0X
- Pharmacologic class
- Vascular Endothelial Growth Factor Receptor 2 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400002766901followed by a unit qualifier and the quantityPackage 00002-7669-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 125477
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cyramzaramucirumab | Ramucirumab 10 mg/mL | SolutionIntravenous | Eli Lilly and Company | 0002-7678 |